Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022]
- Recombinant
- What is this?
4
(2 Reviews)
|
(38 Publications)
Human Recombinant Monoclonal SPIKE antibody. Suitable for ELISA, I-ELISA and reacts with Recombinant full length protein - SARS-CoV-2, Recombinant full length protein - SARS-CoV, Recombinant fragment - SARS-CoV-2 samples. Cited in 38 publications. Immunogen corresponding to Cell preparation containing SARS-CoV-2 Spike Glycoprotein S1 protein.
View Alternative Names
2, S, Spike glycoprotein, S glycoprotein, E2, Peplomer protein
- ELISA
Supplier Data
ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (AB273073)
Binding curve of ab273073 to SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag and SARS-CoV-2 Spike Glycoprotein (S2), Sheep Fc-Tag from HEK293 cells.
ELISA plate coated with SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag (blue line) or SARS-CoV-2 Spike Glycoprotein (S2), Sheep Fc-Tag (orange line) from HEK293 cells at concentrations of 5 μg/ml. A 3-fold serial dilution from 125 ng/ml was performed using ab273073.
For detection, a 1/4000 dilution of HRP-labelled anti-human IgG antibody was used.
- ELISA
Supplier Data
ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (AB273073)
Binding curve of ab273073 to SARS-CoV-2 Spike Glycoprotein domains S1 and S2 of various origin.
ELISA plate coated with SARS-CoV-2 Spike Glycoprotein (S1), His-Tag (Insect Cells; grey line), SARS-CoV-2 Spike Glycoprotein (S2), His-Tag (Insect Cells; yellow line) and SARS Coronavirus Spike Glycoprotein (S1), His-Tag (HEK293 cells; blue line) at concentrations of 5 μg/ml. A 3-fold serial dilution from 41.6 ng/ml was performed using ab273073.
For detection, a 1/4000 dilution of HRP-labelled anti-human IgG antibody was used.
- I-ELISA
Lab
Indirect ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (AB273073)
Indirect ELISA showing primary antibody ab273073 (CR3022, human chimeric) binding to the antigens ab272105 (recombinant human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (sheep Fc fusion)) and ab273068 (recombinant human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Active)). Plates were coated with 100ng/well ab272105 or ab273068 and binding of ab273073 assessed in serial dilution from 200ng/ml primary antibody in duplicate. Binding was detected using ab98624, an anti-human Fc secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.
- ELISA
Unknown
ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (AB273073)
ELISA using ab273073 and mutant spike proteins. The plate was coated with the mutant spike protein variants (The Native Antigen Company) at 2.5 μg/ml. ab01680 was conjugated to HRP and titrated on a 3-fold serial dilution starting at 1,000 ng/ml. CR3022 (ab01680) exhibited exceptional binding to all mutant spike proteins. RBD WT – wild-type receptor binding domain.
- ELISA
Unknown
ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (AB273073)
ELISA using ab273073 with UK (B.1.1.7) and South African (B.1.351 (501Y.V2)) mutant spike proteins. The plate was coated with the mutant spike protein variants (The Native Antigen Company) at 2.5 μg/ml. ab01680 was conjugated to HRP and titrated on a 3-fold serial dilution starting at 1,000 ng/ml. CR3022 (ab01680) exhibited exceptional binding to all mutant spike proteins. WT – wild type.
Reactivity data
Product details
The original CR3022 antibody was generated by sequencing peripheral blood lymphocytes of a patient exposed to the SARS-CoV. This antibody was shown to neutralize SARS-COV in a concerted action with clone CR3014. Presence of both antibodies delivers a blocking action of the SARS-COV RBD-ACE2 interaction, by binding two distinct and functional epitopes (16796401).
CR3022 has been shown to bind with a high affinity to SARS-CoV2 (32416259, 32413276). Structural modelling has confirmed that CR3022 targets a conserved epitope between SARS-CoV and SARS-CoV2 in the RBD domain (32245784, 32065055). Precisely, this antibody binds to the 'open' conformation of the spike protein to the amino acids 318-510 in the S1 domain of the SARS-CoV as well as SARS-CoV-2 strains (32245784, Joyce et al. 2020). The antibody is also able to bind the P462L-substituted S318–510 fragments of the SARS spike protein. The binding epitope of clone CR3022 does not overlap with the ACE2 binding site of SARS-COV2 (32065055). Therefore whilst CR3022 can neutralise SARS-COV in in a concerted action with clone CR3014, CR3022 is not believed to independently neutralise SARS-COV2, based on in vitro studies (32226289, 32065055, 32383254, 32416259).
Recombinant Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody (ab273073) is a Human IgG1 Recombinant version of CR3022 for research use only. CR3022 is also available as a chimeric rabbit antibody (ab273074).
Applications overview
Tick: Tested and Guaranteed to work X: Will not work —: No data
<img src="https://www.abcam.com/ps/Products/273/ab273073/Images/ab273073-394507-applications-overview.jpg" height="125" width="766">
ab273073 was developed to have a human IgG1 isotype.
Other isotypes of clone CR3022 available:
ab278112 – human IgA
ab278111 – human IgM
ab273074 – rabbit IgG
ab273886 – rat IgG2a
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
The spike glycoprotein S1 mediates the fusion of the viral and cellular membranes which is necessary for viral entry. It forms part of a larger trimeric complex comprising S1 and S2 subunits. This complex undergoes conformational changes that drive the membrane fusion process. The glycoprotein contains multiple glycosylation sites which help shield the virus from the host immune response. The proper function and presentation of this glycoprotein are critical for efficient viral spread and infection establishment.
Pathways
The spike glycoprotein S1 is integral to the viral infection pathway and host immune evasion. It interacts with the renin-angiotensin system by binding to the ACE2 receptor disrupting normal receptor activity. This interaction not only facilitates viral entry but also impacts the homeostatic functions typically mediated by ACE2 which include blood pressure regulation. Additionally the spike protein is involved in downstream activation of immune signaling pathways including those related to inflammation and cytokine production which may involve proteins such as IL-6.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (38)
Recent publications for all applications. Explore the full list and refine your search
Immunity & ageing : I & A 22:9 PubMed39994686
2025
Applications
Unspecified application
Species
Unspecified reactive species
ACS sensors 10:1407-1418 PubMed39960416
2025
Applications
Unspecified application
Species
Unspecified reactive species
Viruses 16: PubMed39205315
2024
Applications
Unspecified application
Species
Unspecified reactive species
Nature communications 15:4182 PubMed38755157
2024
Applications
Unspecified application
Species
Unspecified reactive species
Communications medicine 4:62 PubMed38570605
2024
Applications
Unspecified application
Species
Unspecified reactive species
JCI insight 9: PubMed38483534
2024
Applications
Unspecified application
Species
Unspecified reactive species
New biotechnology 80:27-36 PubMed38128698
2023
Applications
Unspecified application
Species
Unspecified reactive species
Cell host & microbe 31:1866-1881.e10 PubMed37944493
2023
Applications
Unspecified application
Species
Unspecified reactive species
BioMed research international 2023:3892370 PubMed37869628
2023
Applications
Unspecified application
Species
Unspecified reactive species
Viruses 15: PubMed37766247
2023
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com